Interactions between d-h-e-45(dihydroergotamine) and Dihydroergotamine nasal (dihydroergotamine nasal)
dihydroergotamine and dihydroergotamine nasal (Major Drug-Drug)
CONTRAINDICATED: Coadministration of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications may potentiate the risk of vasospastic reactions, including coronary artery vasospasm, peripheral vascular ischemia and colonic ischemia, due to additive pharmacologic effects. Acute myocardial infarction due to sustained vasospasm occurred in a premenopausal woman with controlled hypertension and no known history of coronary artery disease following two 2 mg doses of methysergide maleate 12 hours apart and a subcutaneous injection of sumatriptan 6 mg.
MANAGEMENT: The concomitant use of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications, or use within 24 hours of each other, is considered contraindicated.
